SKIN.SW - Cassiopea S.p.A.

Swiss - Swiss Delayed Price. Currency in CHF
40.00
-0.70 (-1.72%)
At close: 5:30PM CET
Stock chart is not supported by your current browser
Previous Close40.70
Open40.50
Bid42.00 x 0
Ask0.00 x 0
Day's Range39.80 - 40.70
52 Week Range36.10 - 57.00
Volume2,721
Avg. Volume2,270
Market Cap400M
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.14
  • PR Newswire

    Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

    LAINATE, Italy, Nov. 13, 2019 /PRNewswire/ -- Cassiopea SpA (SKIN.SW), a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has received approval from the German Authority BfArM and the coordinating ethical committee and will now proceed to enroll the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females. The Phase II multicenter, prospective, randomized, double-blind, vehicle controlled, dose ranging study will evaluate the efficacy and safety of clascoterone solution for the treatment of AGA in females. The four-arm study will enroll 70 subjects per arm in each of four treatment groups: clascoterone solution 5% BID (twice daily), clascoterone solution 7.5% BID (twice daily), minoxidil solution 2% BID (twice daily) and vehicle BID (twice daily).

  • PR Newswire

    Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

    LAINATE, Italy, Nov. 8, 2019 /PRNewswire/ -- Cassiopea SpA (SKIN.SW), a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for clascoterone cream 1%. Cassiopea is seeking marketing approval for clascoterone cream 1% for the treatment of acne.

  • PR Newswire

    Cassiopea Announces FDA Submission of New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

    LAINATE, Italy, Aug. 20, 2019 /PRNewswire/ -- Cassiopea SpA (SKIN.SW), a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for the treatment of acne.